Abstract
Venous thromboembolism (VTE), including deep venous thromboembolism (DVT) and pulmonary embolism (PE), poses clinical and economic burdens in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the risk of developing VTE in patients with NSCLC receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We aim to compare the risk of developing VTE after initiating different EGFR-TKIs in older patients with advanced NSCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
